{"id":"vigiis-101-lab-and-sequential-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a sequential therapy approach developed at National Taiwan University Hospital that combines multiple immunotherapeutic agents administered in a planned sequence to optimize immune priming and effector T-cell activation. The sequential administration strategy aims to overcome immune tolerance and improve therapeutic efficacy compared to single-agent or concurrent approaches.","oneSentence":"Vigiis 101-LAB is a sequential immunotherapy regimen designed to enhance anti-tumor immune responses through coordinated activation of multiple immune pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:15:22.430Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (specific indications not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT03722433","phase":"PHASE4","title":"Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-08-29","conditions":"Helicobacter Pylori Infection","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vigiis 101-LAB and sequential therapy","genericName":"Vigiis 101-LAB and sequential therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vigiis 101-LAB is a sequential immunotherapy regimen designed to enhance anti-tumor immune responses through coordinated activation of multiple immune pathways. Used for Cancer immunotherapy (specific indications not publicly detailed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}